Philips and Spectranetics have announced that they have entered into a definitive merger agreement. Pursuant to the agreement, a press release reports, Philips will commence a tender offer to acquire all of the issued and outstanding shares of Spectranetics for US$38.50 per share to be paid in cash upon completion.
New data presented, by Luca Testa (Department of Cardiology, IRCCS Policlinico S. Donato, Milan, Italy), at EuroPCR (16–19 May, Paris, France) indicates that there is a low rate of clinically relevant bioprosthesis failure nine years after transcatheter aortic valve implantation (TAVI) with a self-expanding device (CoreValve, Medtronic). These data provide reassurance after a study last year suggested that 50% of patients would show signs of valve degeneration after eight years.
Young adults with a history of asthma are at a greater risk of thickening of the left ventricle according to research published today in JACC: Heart Failure.
Novartis has announced topline results from the global Phase III CANTOS study investigating the efficacy, safety and tolerability of canakinumab (ACZ885) in combination with standard of care in people with a prior heart attack and inflammatory atherosclerosis. With more than 10,000 patients enrolled in the study over the last six years, CANTOS is one of the largest and longest-running clinical trials in the company’s history.
A review of the neurological complications that occurred after surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) in the SURTAVI (Surgical replacement and transcatheter aortic valve implantation) trial indicates that there were no significant differences in baseline characteristics between patients who experienced an early stroke and those who did not have a stroke. Furthermore, as seen as in the original SURTAVI findings, TAVI with a self-expanding device (CoreValve/CoreValve Evolut R, Medtronic) was associated with a significantly lower 30-day rate of stroke than was surgery.
Women and their physicians are largely uneducated when it comes to females and heart disease, putting women’s health and lives at greater risk, a new study out today shows.
A study, published in EuroIntervention, provides further evidence that there is an inverse relationship between the number of transcatheter aortic valve implantation (TAVI) procedures a centre performs and in-hospital mortality. However, authors Kurt Bestehorn (Technical University of Dresden, Dresden, Germany) and others caution against setting minimum volume numbers.
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be bridged to a heart transplant with the SynCardia temporary Total Artificial Heart.
Data from the TOPIC (Timing of platelet inhibition after acute coronary syndrome) study indicate that swapping a new potent P2Y212 blocker for the less potent clopidogrel one month after an acute coronary syndrome event in patients receiving dual antiplatelet therapy (DAPT) significantly reduces bleeding events without increasing ischaemic events.
Alexander C Fanaroff (Division of Cardiology, Duke University, Durham, USA) and others report in the Journal of the American College of Cardiology that nearly half of percutaneous coronary intervention (PCI) operators in the USA perform fewer than the recommended target of 50 procedures per year. However, they add that—given that the absolute risk differences between high- and low-volume operators are small—focusing on improving process and outcome performances may be more appropriate than determining an optimal operator volume.
The ARTE study, which was simultaneously presented at EuroPCR (16–19 May, Paris, France) and published in JACC: Cardiovascular Interventions, indicates that dual antiplatelet therapy (DAPT) after transcatheter aortic valve implantation (TAVI)—the current standard approach for reducing the risk of ischaemic events—is associated with a significant increase in the three-month rate of major/life-threatening bleeding events compared with aspirin monotherapy. Furthermore, there were no significant differences between DAPT and aspirin monotherapy in the rates of myocardial infarction, death or ischaemic stroke/transient ischaemic attacks.
The District Court in Munich, Germany has partially found in favour of Edwards Lifesciences Corporation (formerly CardiAQ Valve Technologies) in its case against Neovasc.
Emmanuel Messas (Hôpital Européen Georges Pompidou, Paris, France) and colleagues report in JACC: Basic to Translational Science that pulsed cavitation ultrasound can be used to remotely soften degenerative calcified biosprosthetic valves and significantly improve the valve opening function. They say that this new non-invasive approach has the potential to improve the outcome of patients with severe bioprosthesis stenosis.
Venus Medtech has purchased InterValve, which sells balloon aortic valvuloplasty products and is focused on transcatheter aortic valve treatment. A press release reports that InterValve’s two trademark products—V8 and TAV8—are the world’s pioneering aortic valvuloplasty balloon catheters with anatomical shapes.
Claret Medical has announced that several of the largest centres of excellence for transcatheter aortic valve implantation (TAVI) have now performed the first US cases of protected TAVI with the newly FDA-cleared Sentinel cerebral protection system.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos